Phase Ib/II study of BL-8040 in combination with Atezolizumab in patients with pancreatic cancer
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Atezolizumab (Primary) ; BL 8040 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Genentech
- 08 Aug 2017 This trial is part of MORPHEUS, Roche's Novel Cancer Immunotherapy Development Platform, according to a BioLineRx media release.
- 10 Jul 2017 Status changed from planning to recruitingn according to a BioLineRx media release.
- 01 Jun 2017 According to a BioLineRx media release, Genentech has filed regulatory submissions required to commence this trial.